Novo Nordisk A/S (NYSE:NVO)
| 56.86 Delayed Data As of Dec 11 |  -0.08 / -0.14%Today’s Change | 43.60 Today|||52-Week Range 58.01 | +23.42% Year-to-Date |
Latest NVO News | Press Releases
| Is Sanofi's Stock a Buy? Dec 04 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 56.94 |
| Today’s open | 56.61 |
| Day’s range | 56.58 - 56.92 |
| Volume | 931,807 |
| Average volume (3 months) | 1,431,090 |
| Market cap | $102.3B |
Data as of 6:30pm ET, 12/11/2019
Growth & Valuation
| Earnings growth (last year) | +8.07% |
| Earnings growth (this year) | -0.03% |
| Earnings growth (next 5 years) | +9.77% |
| Revenue growth (last year) | +4.51% |
| P/E ratio | 23.5 |
| Price/Sales | 6.31 |
| Price/Book | 17.07 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | +0.14 | +0.30% |
| LLYEli Lilly and Co | +0.13 | +0.11% |
| SNYSanofi | +0.92 | +1.91% |
| AZNAstraZeneca | +0.21 | +0.44% |
Data as of 6:30pm ET, 12/11/2019
Financials
| Next reporting date | February 5, 2020 |
| EPS forecast (this quarter) | $0.57 |
| Annual revenue (last year) | $17.7B |
| Annual profit (last year) | $6.1B |
| Net profit margin | 34.54% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
